

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 1 of 40	Standard Operating Procedure	

Standard Operating Procedure (Version 5.2)

**published on
EURL ECVAM DataBase service on Alternative Methods to
animal experimentation (DB-ALM)
as Protocol n° 212: epiCS® Skin Irritation Test
(epiCS® SIT)**

epiCS® Skin Irritation Test (epiCS® SIT)

NOTE: *This SOP is completely adopted for the use of epiCS.*

epiCS was formerly known as EST1000 (Epidermal Skin Test 1000)

SkinInVitro GmbH was formerly known as "CellSystems Biotechnologie Vertrieb GmbH"

INDEX

A	Protocol Introduction.....	5
1.	Abstract.....	5
1.1	Changes to the SOP:.....	5
2.	Objectives & Applications.....	5
2.1	Type of Testing:	5
2.2	Level of Toxicity Assessment:	5
2.3	Purpose of Testing:	6
2.4	Context of Use:.....	6
2.5	Applicability Domain:	6
3.	Résumé	6
4.	Experimental Description	6
4.1	Endpoint Detection:	7
4.2	Endpoint Value:	7
4.3	Test System:.....	7
4.4	Basic Procedure:	7
5.	Data Analysis/Prediction Model	8
6.	Test Compounds & Results Summary	8
7.	Modification of the Method	8
8.	Discussion.....	8
9.	Status.....	9
9.1	Known Laboratory Use:	9
9.2	Participation in Validation Studies:	9
9.3	Regulatory Acceptance:	9
10.	Proprietary Issues	10
11.	Abbreviations and Definitions	10

B	Procedure Details, Latest Version: September 2019	11
	Contact Person	11
1.	Health and Safety Issues	11
1.1	General Precautions:.....	11
1.2	MSDS Information:	11
2.	Materials and Preparations	12
2.1	Test Systems:	12
2.2	Standard epiCS Kit Components:	12
2.3	Expiration and Kit Storage:.....	12
2.4	Fixed Equipment:.....	12
2.5	Consumables:.....	13
2.6	Media, Reagents, Sera, Others:	13
3.	Preparations	13
3.1	Media and Endpoint Assay Solutions:.....	13
3.2	Test Compounds:.....	14
3.3	Positive Control Solution: 5 % (w/v) (aq) SDS	14
3.4	Negative Control Solution: Dulbecco’s PBS (DPBS)	14
4.	Interference Tests	14
5.	Test for Mesh Compatibility.....	17
6.	Test Substances.....	18
6.1	Safety Instruction:.....	18
6.2	Liquids:	18
6.3	Solids:.....	18
6.4	Semisolids:.....	19
6.5	Waxes:.....	19
C	Method	20
1.	Routine Procedures:	20
2.	Test Material Exposure Procedures	21
2.1	Test Substance Exposure:	22

- 2.2 Endpoint Measurement:..... 23
- 3. Acceptance Criteria 25
 - 3.1 Assay Acceptance Criterion 1: Negative Control 25
 - 3.2 Assay Acceptance Criterion 2: Positive Control 25
 - 3.3 Assay Acceptance Criterion 3: Standard Deviation (SD)..... 25
 - 3.4 Retesting 26
- 4. Data Analysis 26
- 5. Prediction Model..... 26
- D Annex.....28**
 - 1. Annex A..... 28
 - 2. Annex B..... 29
 - 3. Annex C..... 37
 - 4. Annex D..... 38
- E Bibliography39**

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 5 of 40	Standard Operating Procedure	

A Protocol Introduction

epiCS® Skin Irritation Test (epiCS® SIT)

1. Abstract

The epiCS Skin Irritation Test (epiCS SIT) is used for the classification of chemicals concerning their skin irritating properties. Cytotoxic effects on the commercially available reconstructed epidermis epiCS are determined by a standard MTT assay. The method is available as a kit, comprising reconstructed epidermis, media and culture plates.

epiCS was formerly known as **EST1000** (Epidermal Skin Test 1000).

1.1 Changes to the SOP:

Since the publication of the former version of this SOP (Version 5.1) new developments made this new version (Version 5.2) necessary.

The most important changes are:

1. CellSystems changed name in „SkinInVitro“ as of April 1, 2019
2. page 6 (3) In November 2018 the non-Commission members of the ECVAM Scientific Advisory Committee (ESAC) accepted epiCS- models for in vitro irritations test and adopted the epiCS- models in the TG439 (OECD; 2019)
3. page 6 footnote after Specific acceptance criteria are described in the OECD TG 439 „In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method“ (OECD 2019).
4. Prediction Model „for more details consult OECD TG439 (2019) “
5. page 38 References: 26: OECD, 2019. OECD Guideline for Testing of Chemical, No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method
6. page 38 References: 27: ESAC Opinion on the Validation Study of the epiCS® Test Method based on the EURL ECVAM/OECD Performance Standards for in vitro Skin Irritation Testing using Reconstructed human Epidermis (RhE), ESAC Opinion Number 2016-0
7. page 38 References: 28: Peer Review Report of the Validation of the Skin Irritation Tests Using Skin+® and Using epiCS® (2018)

2. Objectives & Applications

2.1 Type of Testing:

Replacement

2.2 Level of Toxicity Assessment:

Hazard identification, toxic potential, toxic potency

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 6 of 40	Standard Operating Procedure	

2.3 Purpose of Testing:

Classification and labelling; prediction of skin irritation potential.

2.4 Context of Use:

In vitro skin irritation tests are regulatorily accepted.

Performance standards for applying human skin models to *in vitro* skin irritation testing were defined based on the validated test EpiSkin™ test method (ECVAM SIVS, 2007). After the update of the ECVAM performance standards in 2009 (ECVAM 2008, 2009) the “OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method” 439 was adopted in 2010 (OECD 2010). [Last adoption in 2019 \(OECD 2019\)](#)

2.5 Applicability Domain:

The test described in this protocol is designed for the classification of chemicals and was established for liquids, viscous and solid test substances.

3. Résumé

Skin irritation refers to the reversible damage to the skin following the application of a chemical, as defined by the United Nations Globally Harmonized System of Classification and Labelling of Chemicals (UN GHS, UN, 2009). The potential to induce skin irritation is an important consideration for the safe handling, packing and transport of chemicals and produces. The classification has been determined so far by a modification of the *in vivo* Draize rabbit skin test (Draize et al. 1944) and described in the OECD TG 404 (OECD 2002).

The validation study of the epiCS® Skin Irritation Test (SIT) based on the EURL ECVAM/ OECD Performance Standards for *in vitro* skin irritation testing using Reconstructed human Epidermis (RhE) [EURL ECVAM Scientific Advisory Committee (2016) (ESAC OPINION 2016)] and was performed in a ring trial with three participating laboratories. Advanced CellSystems GmbH (ACS), Harlan Cytotest Cell Research GmbH (HCCR) and the Institute for In Vitro Sciences, Inc. (IIVS).) A set of 20 reference test chemicals as specified of the OECD Test Guideline (TG) 439 and EC Testing Method B.46. (In vitro skin irritation: reconstructed human epidermis model test. Council Regulation (EC) No 761/2009) was tested in each laboratory (OECD, 2013) (B 46. (EC) No 761/2009). The evaluation of the catch-up validation study is based and guided by the performance standards (PS) of the OECD TG 439; GD 220 (OECD, 2015), following ESAC opinion in 2016 (ESAC Opinion Number 2016-5) and independent peer review in 2018 (Peer Review Report of the Validation of the Skin Irritation Tests 2018). In November 2018 the non-Commission members of the ECVAM Scientific Advisory Committee (ESAC) accepted epiCS test method for *in vitro* irritations test and adopted the epiCS test method in the TG439 (OECD; 2019)

Specific acceptance criteria are described in the OECD TG439 „In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method” (OECD 2019).

4. Experimental Description

Irritation is generally defined as “the production of reversible inflammatory changes in the skin” (OECD 2002). This is induced by chemicals which penetrate the stratum corneum and lead to

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 7 of 40	Standard Operating Procedure	

damages and cell loss of the underlying cell layers. The epiCS SIT measures the cell damage as reduction of cell viability using a human reconstructed human epidermis.

The test consists of a topical exposure of the neat test chemical to a human reconstituted epidermis model followed by a cell viability test. Cell viability is measured by dehydrogenase conversion of MTT [(3-4,5-dimethyl thiazole 2-yl)-2,5-diphenyltetrazoliumbromide], present in cell mitochondria, into a blue formazan salt that is quantitatively measured after extraction from tissues (Mosmann 1983). The reduction of viability of tissues exposed to chemicals in comparison to negative controls (treated with DPBS) is used to predict skin irritation potential. Recent comparative studies in human skin models employing various endpoints to predict skin irritancy of topical formulations have shown that the MTT endpoint had clear advantages, even over mechanistically based endpoints like the release of IL-1 α (Faller et al. 2002, Faller & Bracher 2002).

4.1 Endpoint Detection:

Cell viability is used as endpoint and measured by dehydrogenase conversion of MTT [(3-4,5-dimethyl thiazole 2-yl)-2,5-diphenyltetrazoliumbromide], present in cell mitochondria, into a blue formazan salt that is quantitatively measured after extraction from tissues (Mossmann 1983). The reduction of viability of tissues exposed to chemicals in comparison to negative controls (treated with DPBS) is used to predict skin irritation potential.

4.2 Endpoint Value:

The cell viability is expressed as percentage of the negative control.

4.3 Test System:

epiCS [SkinInVitro GmbH, Troisdorf, Germany (offered on the market by CellSystems Biotechnologie Vertrieb GmbH)] consists of normal, human-derived epidermal keratinocytes, which have been cultured to form a multi-layered, highly differentiated model of the human epidermis. It consists of organized basal, spinous and granular layers, and a multi-layered stratum corneum containing intercellular lamellar lipid layers arranged in patterns analogous to those found in vivo. A generic description of general and functional conditions that skin models need to comply with can be found in the OECD Test Guideline 439 (OECD 2019).

The epiCS tissues (surface 0.6 cm²) are cultured on specially prepared cell culture inserts and shipped world-wide as kits, containing tissues on agarose together with epiCS Culture Medium, epiCS MTT Assay medium and 6-well plates.

4.4 Basic Procedure:

On day of receipt, epiCS are conditioned by incubation in epiCS Culture Medium for release of transport-stress related compounds and debris at least 4 h or overnight. After pre-incubation, tissues are topically exposed to the test chemicals for 20 min. Three tissues are used per test chemical, positive control (PC) and negative control (NC). Tissues are then thoroughly rinsed and blotted to remove the test substances and transferred to fresh medium. After a 24 h incubation period medium is changed and the tissues are incubated for another 18 h. Afterwards, MTT assay is performed by transferring the tissues to 24 well plates containing 300 μ l MTT medium (1 mg/ml). After a 3 h MTT incubation the blue formazan salt formed by cellular mitochondria is extracted with 2 ml isopropanol

per tissue and the optical density of the extracted formazan is determined in a spectrophotometer at 570 nm. Relative cell viability is calculated for each tissue as % of the mean of the negative control tissues. Skin irritation potential of the test materials is predicted if the mean relative cell viability of the tissue is below or equal 50 %.

5. Data Analysis/Prediction Model

The test protocol allows predicting the skin irritation potential of test substances according to the United Nations Globally Harmonized System (UN-GHS) for classification and labelling. A reduction of tissue viability of equal or below 50 % of the negative control classifies the substances as “category 2”. Tissue viability of above 50 % results in classification as “no category”.

<i>In vitro</i> result	<i>In vivo</i> prediction
mean tissue viability \leq 50 %	category 2
mean tissue viability $>$ 50 %	no category

6. Test Compounds & Results Summary

During the multicentre blind trial validation study, the 20 reference chemicals (10 *in vivo* irritants and 10 *in vivo* non-irritant chemicals) mentioned in the OECD TG 439 In “Vitro Skin Irritation: Reconstructed Human Epidermis Test Method” and EC Testing Method B.46 (B 46. (EC) No 761/2009) were used. Three different laboratories performed the classification process of all chemicals under GLP like conditions followed by an independent statistical analysis.

7. Modification of the Method

None

8. Discussion

The epiCS SIT is an easy to perform *in vitro* test which only needs none or a minimum of training. The protocol is self-explaining. Besides a standard cell culture and chemicals laboratory no special equipment is required.

In contrast to the use of laboratory animals or excised human skin the method offers a high reproducibility due to standardised materials and processes during the production. Furthermore, the epiCS is based on human cells to predict effects on humans and serves as a complete replacement of the *in vivo* acute skin irritation test in rabbits. The material cost for classification of 10 test chemicals and 2 controls is <2000 €. About 5-6 h are needed for practical application for 10 test chemicals and 2 controls. Preparation (~ 1-2 h.), exposure procedures and washing (~ 2 h), MTT viability test (~ 1 h) and data analysis (~ 1 h). In a typical run up to ten chemicals can be tested with 2 technicians. High-throughput testing may be possible if the test will be performed with fully or semi-automated processes.

9. Status

9.1 Known Laboratory Use:

epiCS is used in industry and academia for research, efficacy testing and regulatory toxicology testing (fully validated and accepted for skin irritation and skin corrosivity testing), listed in the OECD TG 439 and OECD TG 431.

9.2 Participation in Validation Studies:

The protocol was developed and refined by CellSystems GmbH (now known as SkinInVitro GmbH) in compliance with the ECVAM performance standards requirements and was part of a blind trial multicentre validation study.

9.3 Regulatory Acceptance:

After the successful validation EURL-ECVAM's Scientific Advisory Committee (ESAC) EURL-ECVAM published the "ESAC opinion" in 2016 (EURL ECVAM Scientific Advisory Committee (2016)). The epiCS test method achieved regulatory acceptance in 2019 [In vitro skin irritation: Reconstructed Human Epidermis Test Method (RHE) (OECD; 2019)]

In OECD TG 439 (OECD; 2019) and EC Testing Method B.46 (B 46. (EC) No 761/2009) it is recommended, prior to a routine use of the test, to check the technical proficiency of the laboratory using ten Proficiency Chemicals listed in the Table below:

Substance	CAS NR	In vivo score in accordance with OECD TG 404	Physical state	UN GHS Category
naphthalene acetic acid	86-87-3	0	Solid	No Cat.
isopropanol	67-63-0	0.3	Liquid	No Cat.
methyl stearate	112-61-8	1	Solid	No Cat.
heptyl butyrate	5870-93-9	1.7	Liquid	No Cat. (Optional Cat.3) *
hexyl salicylate	6259-76-3	2	Liquid	No Cat. (Optional Cat.3) *
cyclamen aldehyde	103-95-7	2.3	Liquid	Cat. 2
1-bromohexane	111-25-1	2.7	Liquid	Cat. 2
potassium hydroxide (5% aq.)	1310-58-3	3	Liquid	Cat. 2
1- methyl-3-phenyl- 1-piperazine	5271-27-2	3.3	Solid	Cat. 2
heptanal	111-71-7	3.4	Liquid	Cat. 2

*Classification of a test chemical under the optional UN GHS Category 3: "Mild Irritant" is currently not possible with the epiCS® SIT as well as other validated RhE models and is not required under EU CLP regulation (No. 1272/2008 EU,2008).

For training SkinInVitro proposes the epiCS® Validation Study Irritation (Ref. CS-1018 VI) and individual trainings (Please contact SkinInVitro about this).

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 10 of 40	Standard Operating Procedure	

10. Proprietary Issues

The intellectual property rights (IPRs) for the test system are held by SkinInVitro GmbH (formerly known as CellSystems Biotechnologie Vertrieb GmbH). No IPRs are associated with the present method.

11. Abbreviations and Definitions

MDS: method documentation sheet

MTT: 3-(4,5-dimethyl-thiazoyl-2-yl)-2,5-diphenyl-tetrazolium bromide

NC: negative control

OD: optical density

PC: positive control

PS: performance standards

ref.: reference

RH: relative humidity

RT: room temperature

SD: standard deviation

SDS: sodium dodecyl sulphate

UN-GHS: United Nations Globally Harmonized System

Last update: Sep. 2019

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 11 of 40	Standard Operating Procedure	

B Procedure Details, Latest Version: September 2019

epiCS® Skin Irritation Test (epiCS® SIT)

Contact Person

M.Sc. Bernadette Thiede

Full Address: SkinInVitro GmbH
Langelier Ring 5
53842 Troisdorf
Germany

Phone: +49 (0) 2241-25515-0
Fax: +49 (0) 2241-25515-30
E-Mail: Bernadette.thiede@skininvitro.com

1. Health and Safety Issues

1.1 General Precautions:

All biological components of the epidermis and the culture medium are tested by manufacturer for viral, bacterial, fungal and mycoplasma contamination.

The epidermal cells are taken from healthy volunteers negative for HIV, and Hepatitis B+C virus. Nevertheless, handling procedures for biological materials should be followed:

Wear gloves during handling with the skin and kit components

After use, the epidermis, the material and all media in contact with it should be decontaminated prior to disposal (e.g. using 10 % bleach, special containers or autoclaving).

Examine all kit components for integrity and deviation from standard appearance.

Please contact SkinInVitro GmbH if you have any questions or concerns.

1.2 MSDS Information:

- Non-coded test chemicals should be handled following chemical safety datasheet.
- SDS (R11, R20/22, R41 –H228, H302 / H332, H315, H318, H335, H412)
Isopropanol (R11, R36, R67 –H225, H319, H336)
MTT (R68, R36/38 –H315, H319, H335, H341)
Work in ventilated cabinets: to prevent accidental contact wear protective gloves, and if necessary, safety glasses.
- Unknown and coded test chemicals with no or incomplete safety handling information should be considered as irritant and toxic and must be handled with maximum care. In accordance with chemical safety guidelines: use safety ventilated cabinet, wear gloves, eye and face protection

2. Materials and Preparations

2.1 Test Systems:

2.2 Standard epiCS Kit Components:

Sealed 24-well plate (epiCS)	Contains up to 24 inserts with epidermis tissues (origin human keratinocytes) on agarose
6-well plates (sterile)	For assay / culture
epiCS Culture Medium	For tissue culture
epiCS MTT Assay medium	For diluting MTT reagent prior to use in the MTT assay

2.3 Expiration and Kit Storage:

reference	description	conditions	shelf life
CS-1001	epiCS (reconstructed epidermis)	refrigerator (2-8°C)	72 h
CS-3050	epiCS Culture Medium: 50 ml	refrigerator (2-8°C)	(see label)
CS-3051	75 ml		
CS-3052	100 ml		
CS-3053	125 ml		
CS-3030	epiCS MTT Assay medium: 25 ml	refrigerator (2-8°C)	(see label)
CS-3031	50 ml		

Note: Examine all kit components for integrity. If there is a concern call immediately.

Phone: + 49 (0)2241-25515-0

2.4 Fixed Equipment:

Laminar flow hood	For safe work under sterile conditions
Humidified incubator (37±1°C, 5±1 % CO ₂ , 90±10 % relative humidity (RH))	For incubating tissues prior to and during assays
Vacuum source/trap (optional)	For aspirating media and solutions
Laboratory balance	For pipette verification and checking spoonful weight
96-well plate spectrophotometer	For reading OD
Plate shaker	For extraction of formazan
Timers	To be used during application of test materials
Sterile, forceps or tweezers	For handling tissue inserts
500 ml plastic wash bottle	For rinsing tissue with DPBS
200 ml beaker	For collecting DPBS rinses
150 ml beaker	For swirling of cell culture inserts
37±1°C water bath	For warming Media and MTT solution
Mortar and pestle	For grinding granular solids
Adjustable pipette	For pipetting 2 ml MTT isopropanol

<i>Adjustable micropipette</i>	<i>For application of 30 µl liquid test materials and 50 µl of DPBS when wetting the tissue surface before application of solid substances</i>
<i>Positive displacement pipette 30 µl</i>	<i>For application of semi-solid test materials</i>
<i>Sharp spoon</i>	<i>For application of solids (Aesculap, ref. FK 623)</i>

2.5 Consumables:

<i>96-well plate</i>	<i>For the MTT assay</i>
<i>24-well plate</i>	<i>For the MTT assay</i>
<i>Sterile paper towel</i>	<i>For blotting of cell culture inserts</i>
<i>Meshes (Nylon) (CellSystems, ref. CS-5010)</i>	<i>Use as a spreading aid for liquid test materials</i>
<i>Extra 6-well plates – sterile</i>	<i>To transfer tissue inserts to fresh media (instead of replacing the media using the same plate)</i>
<i>Adhesive tape (NeoLab ref. 7-2220 or ref. 2-5082) or Parafilm M</i>	<i>Covering plates during formazan extraction</i>
<i>Injection needle</i>	<i>MTT-Assay</i>

2.6 Media, Reagents, Sera, Others:

<i>Dulbecco's PBS (DPBS) Ca/Mg-free (sterile)</i>	<i>Use for rinsing tissues</i>
<i>5 % (w/v) SDS in sterile deionised water; [151-21-3] (Sigma ref. L-4509, purity min. 98.5±1 %)</i>	<i>To be used as positive control</i>
<i>MTT - Thiazolyl Blue Tetrazolium Bromide (Sigma, ref. M-5655, cell culture tested, purity min. 97,5 %)</i>	<i>For MTT assay</i>
<i>Isopropanol</i>	<i>For extraction of the formazan crystals</i>

3. Preparations

3.1 Media and Endpoint Assay Solutions:

MTT Solution (prepare freshly on day of testing)

Per 24 tissues, dissolve 12.5 mg MTT (Sigma ref. M5655) in 12.5 ml epiCS MTT Assay medium and thoroughly vortex this stock-solution. Keep the MTT medium in the dark and warm to 37°C prior to usage (Use within 2 h).

Safety precaution: MTT is toxic (Risk phrases: R26, R68, R22, R36, R37, R38).

Wear protective gloves during manipulation with MTT solution!

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 14 of 40	Standard Operating Procedure	

Dulbecco's PBS (DPBS) for rinsing

Sterile ready-to-use DPBS should be used. About two litres are sufficient for all rinsing performed with one kit. If DPBS is prepared from 10x concentrates or powder, pH needs to be adjusted to 7.0 ± 0.1 and solution must be sterilized. Record the preparation in the MDS.

3.2 Test Compounds:

Follow safety instructions for respective compounds. The mode of application onto the tissues differs depending on substance consistency (liquid / viscous / solid); see chapter "Test substances".

3.3 Positive Control Solution: 5 % (w/v) (aq) SDS

Weigh out 0.50 g SDS (analytical grade, see equipment) into an appropriate calibrated 10 ml flask and complete with distilled water to 10 ml (final volume). For better solubilisation of SDS place solution in a water bath ($37\pm 1^\circ\text{C}$) for 10 min. Solution can be stored up to one month ($2-8^\circ\text{C}$). Record the preparation in the MDS.

3.4 Negative Control Solution: Dulbecco's PBS (DPBS)

Sterile ready-to-use DPBS should be used. If DPBS is prepared from 10x concentrates or powder, pH needs to be adjusted to 7.0 ± 0.1 and solution must be sterilized.

4. Interference Tests

The current OECD TG 439 makes provisions for interference tests. (See chapter 30ff (OECD TG 439, 2019)).

Test for interference of chemicals with MTT endpoint and correction procedures

A test substance may interfere with the MTT endpoint if: a) it is coloured and/or b) able to directly reduce MTT (for possible combination of interactions, see Annex D). The MTT assay is affected only if the test material is present in or on the tissues when the MTT viability test is performed.

Some non-coloured test materials may change into coloured materials in wet or aqueous conditions and thus stain tissues during the 20 min exposure. Therefore, before exposure, a functional check for this possibility should be performed (Step 1).

Step 1:

Add 30 μl (liquid) or 30 mg (solid) of the test substance into 0.3 ml of deionised water. Perform the test in a transparent, preferably glass test tube since plastic test tubes may react with the test articles during the incubation time. Incubate the mixture in the incubator ($37\pm 1^\circ\text{C}$, $5\pm 1\%$ CO_2 , $90\pm 10\%$ RH) for 60 min. At the end of the exposure time, shake the mixture and evaluate the presence and intensity of the staining (if any). If the solution changes colour significantly, the test substance is presumed to have the potential to stain the tissue. A functional check on viable tissues should be performed (Step 2).

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 15 of 40	Standard Operating Procedure	

Step 2:

To check the tissue-binding of a coloured test article (or a chemical that changes into a coloured substance) the following test should be performed ideally with 3 tissue replicates (at least 2) concurrently tested with each and every test performed with the coloured chemical (using the same tissue batch): Expose three tissues replicates to 30 µl of liquid test substance or 30 mg of solid test substance. In parallel, expose a tissue to DPBS (negative control). Follow all procedures as described in this protocol in the method section except incubate the tissue for 3h in epiCS MTT Assay medium without MTT (37±1°C, 5±1 % CO₂, 90±10 % RH) instead of incubating in epiCS MTT Assay medium containing MTT. After the 3 h incubation, rinse the tissues and extract the tissues using 2.0 ml of isopropanol and measure the optical density (OD) at 570 nm.

Data Correction Procedure

If the extract from tissues treated by coloured substance (or substance detected in step 1) has an OD between 5 % and 30 % of the negative control tissue (treated with DPBS), the chemical should be concurrently tested with each and every test performed with the coloured material using the procedure described above. The OD (unaffected by interference with the coloured test materials) is calculated using following formula:

$\text{OD} = \text{OD coloured tissue (MTT assay)} - \text{OD coloured tissue (no MTT assay)}$
--

Note: *If the extract from tissues treated by coloured substance (or substance detected in Step 1) has an OD <5% of the DPBS treated control tissue and the tissue viability (determined in MTT assay) is not close to the classification cut-off (50 %), correction of the results is not necessary.*

If the OD of extract from the tissue treated by coloured substance (or substance detected in Step 1) is > 30 % of the DPBS treated control tissue, additional steps and expert judgment must be performed to determine if the test substance must be considered as incompatible with the test.

Step 3:

All test materials (including those already evaluated in Step 1 and Step 2) should be further evaluated for their potential to interfere with MTT assay. To test if a material directly reduces MTT, add 30 µl (liquid) or 30 mg (solid) of the test substance to 1 ml of the epiCS MTT Assay medium containing MTT and incubate in the incubator (37±1°C, 5±1 % CO₂, 90±10 % RH) for 60±2 min. As negative control uses 1 ml epiCS MTT Assay medium containing MTT. If the MTT solution turns blue/purple, the test substance reduces MTT and additional functional check (Step 4) must be performed.




Figure 1: Example of test for direct MTT reduction ability (Step 3). Test substances (2) (3) and (6) have directly reduced MTT. In these cases, Step 4 must be performed.

Step 4:

The procedure employs freeze-killed tissues that possess no metabolic activity but absorb and bind the test substance like viable tissues.

finished-produced freeze-killed tissues, they can purchase at CellSystems GmbH:

<i>reference</i>	<i>description</i>	<i>conditions</i>	<i>shelf life</i>
CS-1001F	epiCS-frozen	Freezer (-20°C)	(see label)

Prepare freeze-killed tissues:

- a) transfer epiCS in 24-well plates
- b) freeze tissue at -20°C (or -80°C) for at least 48 h (3 tissues / MTT-interacting test substance)
- c) thaw tissue 1 h (± 10 min) before use
- d) keep at RT

Correction of nonspecific MTT reduction should be performed with 3 tissue replicates in a single run, independently of the number of independent tests performed with the direct MTT reducing chemical:

Each MTT reducing chemical is applied to three freeze-killed tissue replicates. In addition, three freeze killed tissues are left untreated (Note: The untreated killed controls will show a small amount of MTT reduction due to residual reducing enzymes within the killed tissue). The entire assay protocol is performed with the frozen tissues in parallel to the viable epiCS tissues. Data are then corrected as follows:

Data Correction Procedure

$$\begin{aligned} \text{True viability} &= \text{Viability of treated tissue} - \text{MTT conversion by chemical} \\ &= \text{OD tvt} - \text{OD kt} \\ \text{OD kt} &= (\text{mean OD tkt} - \text{mean OD ukt}) \end{aligned}$$

tvt = treated viable tissue kt = killed tissues

tkt = treated killed tissue ukt = untreated killed tissue (NC treated tissue)

Note: *If the coloured test material or the MTT reducing chemical is classified as irritant by the Skin Irritation Test (tissue viability $\leq 50\%$), the correction procedures are not necessary.*

5. Test for Mesh Compatibility

Capillary effects (surface tension effects) were observed if low volumes of lipophilic liquid test chemicals were topically applied on epiCS tissues. Therefore, a nylon mesh is used as a spreading support for all substances (both liquids and solids)

Some chemicals may react with the mesh and therefore the compatibility of each chemical with nylon mesh has to be checked.

To test if a test chemical interacts with the mesh, place the mesh on a slide and apply 30 μl test substance or 50 μl of DPBS and 30 mg of a solid test substance. After 60 min exposure, check using a light microscope, if an interaction between test substance and the mesh is noticed (Figure 2, right side). In that case the test substance has to be applied without using a mesh as a spreading aid.




Figure 2: The mesh compatibility test

6. Test Substances

6.1 Safety Instruction:

1. For handling of known test substances follow instructions given in the Material Safety Data Sheet.
2. If coded materials or unknown samples are supplied, no (or possibly incomplete) information regarding the safe handling will be provided. Therefore, all test materials must be treated as if they were irritating and toxic and work must be performed in accordance with chemical safety guidelines (use ventilated cabinet, wear gloves, protect eyes and face).
3. Store all test substances according to recommendations. Respect special storage conditions (special temperature, protection from light, protection from oxidization by nitrogen, etc.)

6.2 Liquids:

Dispense 30 µl directly atop the tissue. Avoid contact with the tissue surface. Afterwards place carefully the nylon mesh on the tissues surface. If necessary, gently position the mesh using pipette tip or tweezers/forceps.




Figure 3: Application of liquids

6.3 Solids:

If necessary, crush and grind test material in a mortar with pestle. Shortly before application of the solid substance, moisten the tissue surface with 50 µl of sterile DPBS to improve contact of the tissue surface with the test chemical. Fill a sharp application spoon with fine ground 30 mg test material (see fig. 4). A pipette tip can be used to empty the spoon completely. It is essential that the whole surface of the epiCS tissue is covered with the test substance. If this is not the case apply additional test substance to secure the coverage of the surface.

Do not press onto the tissue surface. Document all observations concerning the solubility of the material in the MDS. Record in the MDS if grinding was not necessary. Afterwards carefully place the nylon mesh on the tissues surface. If necessary, gently position the mesh using pipette tip or tweezers/forceps.



Figure 4: Application of solids

6.4 Semisolids:

Dispense 30 µl using a positive displacement pipette directly atop the tissue. If necessary, spread the chemical with a pipette tip. Afterwards carefully place the nylon mesh on the tissues surface. If necessary, gently position the mesh using pipette tip or tweezers/forceps.



Figure 5: Application of semisolids (positive displacement pipette - detail)

6.5 Waxes:

For test substances with waxy consistency the spoon application will not work. In these cases, try to form a flat “cookie like” piece of about 8 mm diameter and place it atop the tissue, which is pre-wetted with 50 µl sterile DPBS. To improve the contact between test substance and tissue weigh down the “cookie” with a stainless-steel aid like that shown in Figure 6.



Figure 6: The stainless-steel aid used application of waxy materials

Note: *Highly volatile toxic test substances may affect neighbored tissues within the same 6-well treatment plate. In these cases, plates should be covered with an adhesive plate cover, or other measures should be considered, like testing the volatile substances on separate plates.*

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 20 of 40	Standard Operating Procedure	

C Method

Experimental System Procurement

SkinInVitro GmbH

Langler Ring 5

53842 Troisdorf

Germany

Phone: +49 (0) 2241-25515-0

Fax: +49 (0) 2241-25515-26

E-mail: info@skininvitro.com

1. Routine Procedures:

Day prior to testing (day 0)

1. Upon receipt of the shipment, examine all kit components for integrity. If there is a concern call CellSystems immediately.

Contact person:

M.Sc Bernadette Thiede

SkinInVitro GmbH

phone: +49 (0) 2241-25515-0

email: bernadette.thiede@skininvitro.com

2. Document all information about supplied material in the MDS.
3. Place the DPBS into the refrigerator (2-8°C) and the vial containing the MTT concentrate in the freezer (-20±5°C).

Tissue Conditioning:

1. *Do not pre-warm epiCS Culture Medium!*
2. Pipette exactly 1.0 ml of the cool epiCS Culture Medium into each well of sterile 6-well plates. (For 24 inserts prepare eight 6-well plates. Use one 6-well plate for pre-incubation of three inserts).
3. Remove the shipped multi well plate from the package. Under sterile conditions carefully (using sterile tweezers) take out each insert containing the epiCS tissue. Remove any remaining agarose that adheres to the outer sides of the insert by gentle blotting on the sterile blotting paper and place the tissues in one well of the prepared 6-well plate. Avoid air bubble formation underneath the tissue culture insert.

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 21 of 40	Standard Operating Procedure	

- Perform visual inspection of the inserts within next 5 min. Record any tissue defects and excess of moisture on the surface. Do not use defect tissues or tissues with excessive moisture on the surface.

Note: For detailed evaluation a dissecting stereoscope (magnification 5 X) can be used.

- Incubate the plates at least for 4 h or overnight $37\pm 1^{\circ}\text{C}$, $5\pm 1\%$ CO_2 , $90\pm 10\%$ RH).
- Store remaining epiCS MTT Assay medium refrigerated ($2-8^{\circ}\text{C}$).

Note 1: Air bubbles trapped underneath the insert should be released.

Note 2: The visual quality check of the tissues must be done quickly

Do not use tissues which are completely covered with liquid!!!

- If necessary, prepare sufficient amount of rinsing DPBS for the next day (approximately 1L per 24 inserts).
- Prepare and sterilize all devices which will be used in the assay:
 - Micropipette
 - washing bottles (UV/ gamma irradiation or 70 % ethanol)
 - blotting paper (autoclave)
 - sharp spoon for application of solids (70 % ethanol)

2. Test Material Exposure Procedures

Chemical exposure (day 1)

- Place all devices, solution and chemicals needed for the test in the sterile hood.

Checklist:

- sterile meshes
- Micropipette
- sterile washing bottles pre-filled with sterile DPBS
- sterile blotting paper
- sterile tips and pipettors
- vials with chemicals set to room temperature, including negative control (NC) sterile DPBS and as positive control (PC) 5 % SDS
- timer
- sharp, pointed tweezers
- sharp spoon
- beaker for waste material

Note: Wipe all non-sterile material bottles with 70 % ethanol.

- Prepare enough 6-well plates pre-filled with 1 ml of pre-warmed ($37\pm 1^{\circ}\text{C}$) epiCS Culture Medium in the upper row.

Note: Use one plate per one chemical during exposure and later on during the post-incubation phase to avoid cross contamination!

3. Remove 6-well plates from the incubator approximately 5 min before exposure to chemicals.
4. Check the surface of tissues and exclude completely wet tissues or tissues with any visible defects.
5. Before test substance exposure, label all 6 well plate lids with the test material codes or names.

2.1 Test Substance Exposure:

1. Apply 30 µl or ~30 mg of the undiluted chemical, NC or PC to three single tissues (triplicates) each according to the PREPARATIONS section. Apply chemicals at the time intervals needed later for rinsing off the chemical (recommended intervals are 1,5 to 2 min). Use 50 µl DPBS to moisten tissues before applying a solid chemical. Apply each epiCS tissue with a sterile mesh.
2. Keep plates with applied chemical in the laminar hood at RT (20±2°C) expose test chemical to the tissue for 20±1 min.

Note: Good rinsing tissues are a very important step that removes residual chemicals from the tissue surface. Chemical residues may have large influence on the outcome of the test method. So, rinsing and washing have to be carried out thoroughly and as described in this protocol in the following paragraphs.

3. Rinse tissues with sterile DPBS using a squeeze wash bottle. Fill and empty the tissue insert 20 times to remove any residual test material (Figure 7). Use constant stream of DPBS applied from ~1.5 cm distance from the tissue surface. The stream of DPBS should not be too soft; otherwise, the test chemical may not be removed. Optimal wash bottle, with pointed endings as shown in Figure 7.
Ensure that the mesh is removed after washing three to five times. If the mesh still sticks to the tissue remove it carefully by using tweezers or forceps without damaging the epiCS tissue.
4. Completely submerge and swirl the insert 3 times in 150 ml DPBS (separate beaker per test or control article) to remove remaining test chemicals.




Figure 7: Washing procedure

5. Finally, rinse the tissue once again by repeating step 3 (with 20 more rinses) and after this once from outside with sterile DPBS. Remove excess DPBS by gently shaking the insert, blot insert on sterile blotting paper (Figure 8).

6. Transfer blotted tissue inserts to new 6 well plates pre-filled with fresh pre-warmed (RT-37°C) epiCS Culture Medium. Use one 6-well plate per test substance to avoid potential cross contamination within one plate.
7. Incubate tissues in the incubator for another 24±2 h (37±1°C, 5±1 % CO₂, 90±10 % RH). Record starting time of incubation in the MDS.



Figure 8: Blotting and drying of the surface

Medium change (day 2)

Exchange the medium for each tissue 24 h after the application of the test samples and place the 6 well plates back into the incubator for additional 18±2 h post-incubation (37±1°C, 5±1 % CO₂, 90±10 % RH).

2.2 Endpoint Measurement:

MTT viability test (day 3)

MTT assay

1. Prior to the MTT assay, label enough 24-well plates.
2. Prepare MTT medium as described above and pipette 300 µl of MTT medium to each well.
3. Remove inserts from the 6-well plates, blot bottoms, and transfer them into the 24-well plates, pre-filled with 0,3 ml of MTT (1 mg/ml). Place the plates in the incubator (37±1°C, 5±1 % CO₂, 90±10 % RH), record start time of MTT incubation in the MDS and incubate for 3 h ± 5 min.

Note: Keep 3 h ± 5 min MTT incubation time strictly. Deviation from the 3 h time for MTT incubation will result in different MTT values.

4. After MTT incubation is completed, gently aspirate MTT medium from all wells. Immerse the inserts by gently pipetting 2 ml extracting solution (isopropanol) into each insert. The level will rise above the upper edges of the insert, thus completely covering the tissues from both sides.
5. Seal the 24 well plates (e.g. with parafilm or gas non-permeable adhesive tape) to inhibit isopropanol evaporation. Record start time of extraction in the MDS and extract formazan for at least 2 h (maximum 2,5 h) at room temperature with gently shaking on a plate shaker

(~ 100 rpm). Or Extract either over night without shaking at room temperature (we recommend at 4-8°C to reduce isopropanol evaporation).

- After the extraction period is complete, pierce the inserts with an injection needle (~gauge 20, ~ 0,9 mm diameter, Fig. 9) and allow the extract to run into the well from which the insert was taken. Afterwards the insert can be discarded. Before transferring the extract to 96 well plates pipette up and down 3 x until solution is homogenous.



Figure 9: Piercing the inserts

- Per each tissue transfer 2 × 200 µl aliquots of the blue formazan extracting solution into a 96-well flat bottom microtiter plate according to fixed plate design given in [spreadsheet](#) (example is given in Figure 10). Use isopropanol as blanks. Read OD in a 96-well plate spectrophotometer using a wavelength between 550 and 570 nm preferably at 570 nm, without using a reference filter.

PLATE 1													
	1	2	3	4	5	6	7	8	9	10	11	12	
	BL	BL	BL	BL	BL	BL	E	E	E	E	E	E	A
Tissue 1	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	B
	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C
Tissue 2	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	D
	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	E
Tissue 3	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	F
	NC	PC	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	G
	E	E	E	E	E	E	E	E	E	E	E	E	H

NC - Negative control; PC – Positive control; C1, C2 - Chemical No. 1, No. 2
BL – Blank; E – Empty

Figure 10: Fixed 96 well-plate design (for OD reading in plate spectrophotometer, 2 aliquots per tissue)

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 25 of 40	Standard Operating Procedure	

In contrast to normal spectrophotometers, in plate readers pipetting errors may influence the OD. Therefore, 2 formazan extract aliquots will be taken from each tissue extract. In the Excel data sheet, these 2 aliquots will be automatically reduced to one value by calculating the mean of the two aliquots. Thus, for calculations from each single tissue only one single mean OD-value is used. The plate map is according to the plate design used in the spreadsheet, which is used in the validation study for data collection and preliminary calculations. It is necessary to strictly keep the plate design given here. Otherwise, the calculation of results will be incorrect.

Note: Readings are performed without reference filter, since the "classical" reference filter often used in the MTT test (630 nm) is still within the absorption curve of formazan. Since filters may have a \pm tolerance in some cases the reference filter reduces the dynamics of the signal (OD) up to 30 %.

3. Acceptance Criteria

3.1 Assay Acceptance Criterion 1: Negative Control

The absolute OD of the negative control (NC) tissues (treated with sterile DPBS) in the MTT-test is an indicator of tissue viability obtained in the testing laboratory after shipping and storing procedures and under specific conditions of use.

The assay is meeting the acceptance criterion if the mean OD₅₇₀ of the NC tissues is ≥ 1.0 and does not exceed 2.8

3.2 Assay Acceptance Criterion 2: Positive Control

A 5 % SDS (in H₂O) solution (see Preparations) is used as positive control (PC) and tested concurrently with the test chemicals. Concurrent means here the PC has to be tested in each assay, but not more than one PC is required per testing day. Viability of positive control should be within 95 \pm 1 % confidence interval of the historical data.

The assay is meeting the acceptance criterion if the mean viability of PC expressed as % of the negative control is ≤ 20 %.

3.3 Assay Acceptance Criterion 3: Standard Deviation (SD)

Since the test skin irritancy potential is predicted from the mean viability determined from three single tissues, the variability of tissue replicates should be acceptably low.

The assay is meeting the acceptance criterion if the SD calculated from individual tissue viabilities of the 3 identically treated replicates is < 18 %

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 26 of 40	Standard Operating Procedure	

3.4 Retesting

A single test run composed of three replicate tissues should be sufficient for a test chemical when the classification is unequivocal. However, in cases of borderline results, such as non-concordant replicate measurements and/or mean percent viability equal to 50 ± 5 %, a second run should be considered, as well as a third run in case of discordant results between the first two runs.

4. Data Analysis

A blank, MS EXCEL spreadsheet Annex_III_epiCS_SIT_Spreadsheet.XLS can be provided by SkinInVitro. A copy should be made before the first data entry. The spreadsheet consists of two single tabs named: IMPORT and SPREAD.

Data files of optical densities (OD) generated by the microplate reader (without blank subtraction) are copied from the reader software to the Windows Clipboard and then pasted into the first tab of the EXCEL spreadsheet (IMPORT). The blank corrections, calculation of results and statistical parameters are done automatically in the second part of the spreadsheet (SPREAD).

Use the fixed 96-well plate design as specified in the SOP (see Figure 10). In addition to the entry of the reader raw data, some requested information has to be filled in the first map of the spreadsheet: tissue lot numbers, test material codes, date and lab personnel.

After data entry, the following calculations will be performed on the spreadsheet;

- Blank correction
- For each individual tissue treated with a test substance (/chemical) (TS), the positive control (PC) and the negative control (NC), the individual relative tissue viability is calculated according to the following formulas

$$\text{Relative viability TS (\%)} = [\text{OD}_{\text{TS}} / \text{mean of OD}_{\text{NC}}] \times 100$$

$$\text{Relative viability NC (\%)} = [\text{OD}_{\text{NC}} / \text{mean of OD}_{\text{NC}}] \times 100$$

$$\text{Relative viability PC (\%)} = [\text{OD}_{\text{PC}} / \text{mean of OD}_{\text{NC}}] \times 100$$

- For each test substance, negative control and the positive control the mean relative viability of the three individual tissues is calculated and used for classification according to the Prediction Model.
- The spreadsheet shows a graph of the results (% of relative viability \pm Standard Deviation (SD)).
 - Per each experiment, make a hardcopy of the raw data (i.e. outcome of the reader data).
 - Per each experiment, save your secondary data in one copy.
 - "Annex_III_epiCS_SIT_Spreadsheet.XLS"
 - Fill in the requested information in "Annex_III_epiCS_SIT_Spreadsheet.XLS "
 - In addition, per each experiment, keep signed hardcopies of "Annex_III_epiCS_SIT_Spreadsheet.XLS" together with the signed hardcopy of the MDS.

5. Prediction Model

The test protocol allows predicting the skin irritation potential of test substances according to the United Nations Globally Harmonized System (UN-GHS) for classification and labelling. A reduction of

tissue viability of equal or below 50 % of the negative control classifies the substances as category 2.
Tissue viability of above 50 % results in classification as no category.


<i>In vitro result</i>	<i>In vivo prediction</i>
<i>mean tissue viability \leq 50 %</i>	<i>category 2</i>
<i>mean tissue viability $>$ 50 %</i>	<i>no category</i>

D Annex

1. Annex A

Skin Irritation Test

FLOWCHART



2. Annex B

Method Documentation Sheet (MDS)

Assay:.....

Date:

Corresponding XLS data file name:

Performed by: Signatures:

Time Protocol

Receipt of epiCS (**date, day, hour**):

.....

ID:

Experimental schedule

Procedure	Date (dd-mm-yy)	Set 1		Set 2		Remark
		start	stop	start	stop	
Pre-incubation 1 (1 h)						
Pre-incubation 2 (18 ±3 h)						
Exposure (20 ±1 min)						
Washing						
Post-incubation 1 start (24 ±2 h)						
Medium change (24 h after exposure ±2 h)						
Post-incubation 2 start (18 ±2 h)						
MTT test (3 h ±5 min)						
Extraction (2-2,5 h)						
Measurement						

Devices Verification

Incubator verification

Incubator #	CO ₂ < 5 ±1 % >	Temperature < 37 ±1°C >	Check water in reservoir (✓)

ID/ Date:

Refrigerator verification

Refrigerator #	Temperature < 2-8°C >

ID/ Date:

Water bath verification

Water bath #	Temperature < 37 ±1°C >

ID/ Date:

In case that your devices are controlled by central computer, fill in the following table instead of the fields above:

Name of the device	device #	reference

ID/ Date:

Pipette verification (triplicate)

Pipette 3 x H₂O into a small beaker on a laboratory balance and record readings in grams (g)
 Perform pipette verification once per week and refer to it in all assays of that week. If adjustable pipettes are used, check adjustment daily.

	0.9 ml	2 ml	300 µl	200 µl	25 µl	30 µl
H ₂ O weighting.....					
1.						
2.						
3.						
Mean						
SD						

ID/ Date:

epiCS KIT COMPONENTS

epiCS (CS-1001), tissue Lot no.:		Production date:
epiCS Culture Medium (CS-3050, CS-3051, CS-3052, CS-3053) Lot no.:		Expiration date:
epiCS MTT Assay medium (CS-3030, CS-3031)	Lot no.:	Expiration date:
Sterile Meshes (CS-5010)	Lot no.:	Expiration date:
Position of ice-packs: (direct contact of the ice-packs with the skin must be avoided)		
Other remarks		

ID/ Date:

VISUAL QUALITY CONTROL OF THE SKIN

Use scores: 1- very good, 2- good, 3- acceptable, 4- not acceptable

APPEARANCE	KIT 1	KIT 2
MACROSCOPICALLY		
No of excluded tissues with: - edge defects - air bubbles - extensive moisture on the surface		

Specific observations:

SOLUTIONS

Positive Control

SDS 5 % solution in distilled sterile water (w/v):

- SDS reference, batch no.:
- Weight:
- Distilled water, volume added:
- Preparation date:
- Expiration date:
- Storage: Refrigerator no.:

Note: In case that if you are preparing your own MTT stock solution and/or DPBS fill in the following forms

DPBS Solution Preparation:

- Preparation date:
- pH adjustment (to 7.0):
- Type of sterilisation:
- Preparation date:
- Expiration date:

Dosing Procedure

Tick (✓) in the columns the type of application (pipette, patch, spoon...),
 (**P**: pasty; **V**: viscous; **W**: waxy; **ST**: sticky; **C**: creamy)

Code	Liquid/ Solid (L/S)	Application (30 mg / 30 µl)					Remarks
		Pipette (✓)	Mesh (✓)	Spoon (✓)	Pin (✓)	Wetting (✓)	

ID/ Date:

Remarks to Single Tissues

If you observe any abnormality during the assay, you must substitute tissues, or deal with any technical problems, fill in the following table.

Record the tissue number, substance code and your observation or remark.

Substance code	Tissue no.	Remark

ID/ Date:

MTT Plate Configuration

PLATE 1

1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24

PLATE 2

1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24

ID/ Date:

Spectrophotometry Measurement

Plate Configuration for Reading (for transfer to Spreadsheet epiCS-SI-Spreadsheet.xls): Record the positions of substances on 96-well plate.

Strictly adhere to the fixed plate design of this SOP.

1	2	3	4	5	6	7	8	9	10	11	12	
BLANK	BLANK	BLANK	BLANK	BLANK	BLANK	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	
NC	PC											Tissue1
NC	PC											Tissue2
NC	PC											Tissue3
NC	PC											
BLANK	BLANK	BLANK	BLANK	BLANK	BLANK	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	

Note: switch on the reader 10 min before reading

Check plate photometer filter
Tick correct (✓) filter setting

reading filter:	
570 (550-570) nm	
no reference filter	

ID/ Date:

ARCHIVING

Raw data saved in/as:

Spreadsheet saved in/as:

MDS saved in/as:



3. Annex C

Characterisation of Test Substances

Code	Physical state (solid (S) / liquid (L))	Colour	MTT reduction (+ / -)	Reaction with mesh (+ / -)	Remarks			
					known R- phrase s	known S- phrase s	special storage requirem ents	other

4. Annex D

Test for interference of chemicals with MTT and correction procedures

Water colouration (Step 1, Section 7.3)	Tissue staining (Step 2, Section 7.3)	MTT interaction (Step 3, Section 7.3)	Test conditions
-	-	-	A
+	-	-	A
-	+	-	B
+	+	-	B
-	-	+	C
+	-	+	C
-	+	+	B+C
+	+	+	B+C

Test conditions obtained

A

Perform all steps according to the basic SOP. Correction of results using additional controls is not needed

B

Perform Step 2, Section 7.3 in addition to the basic SOP. Correction of results with viable tissue is needed

C

Perform Step 4, Section 7.3 in addition to the basic SOP. Correction of results with freeze-killed tissue is needed

B + C

A coloured chemical (or a chemical that may turn coloured after interaction with water) may cause both tissues staining and false MTT reduction. If the experimenter is interested in the correction of results, combination of test condition C is enough for this purpose, since the frozen tissues absorb approximately the same amount of chemicals (and colour) as the viable tissues. However, since the frozen tissues are more hydrated than viable tissues, tissue staining by water soluble colourant (or colourless chemicals that will turn in aqueous conditions into coloured) can be overestimated. In addition, conditions may arise when information on the amount of non-specific colouration is required. For increased precision of the above-mentioned case, Steps 2 & 4 (Section 7.3) need to be performed.

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 39 of 40	Standard Operating Procedure	

E Bibliography

1. Botham, P.A., Earl, L.K., Fentem, J.H., Roquet, R., Van DE Sandt, J.J.M., **1998**. *Alternative methods for skin irritation testing: the current status, ECVAM Skin Irritation Task Force Report 1*. ATLA 26, 195-211.
2. Cotovio, J., Grandidier, M-H., Portes, P., Roguet, R., Rubinstenn, G., **2005**. The *In Vitro* Acute Skin Irritation of Chemicals: Optimisation of the EPISKIN Prediction Model within the Framework of the ECVAM Validation Process. ATLA 33, 329–349.
3. Draize J.H., Woodand G. & Calvery H.O. **1944**. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *Journal of Pharmacology and Experimental Therapeutics*. 82, pp 337-390.
4. ECETOC, **1995**. *Skin Irritation and Corrosion: Reference Chemicals Data Bank ECETOC Technical Report No. 66*. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels.
5. ECVAM **2008**. Statement on the scientific validity of *in vitro* tests for skin irritation testing, issued by the ECVAM Scientific Advisory Committee (ESAC29)
6. ECVAM **2009**. Performance Standards For *In-Vitro* Skin Irritation Test Methods Based On Reconstructed Human Epidermis
7. Faller, C., Bracher, M., **2002**. *Reconstructed skin kits: Reproducibility of cutaneous irritating testing*. *Skin Pharmacol Appl Skin Physiol* 15 (suppl 1), 74-91.
8. Faller, C., Bracher, N., Dami, N., Roguet, **2002**. *Predictive ability of reconstructed human epidermis equivalents for assessment of skin irritation of cosmetics*. *Toxicology in Vitro* 16 (5), 557-572.
9. Fentem, J.H., Briggs, D., Chesné, C., Elliott, G.R., Harbell, J.W., Heylings, J.R., Portes, P., Roguet, R., Van De Sandt, J.J.M., Botham, P.A., **2001**. *A prevalidation study on in vitro tests for acute skin irritation: results and evaluation by the Management Team*. *Toxicology in Vitro* 15, 57-93.
10. Heylings, J.R., Diot,., Esdaile, D.J., Fasano, W.J., Manning, L.A., Owen H.M. **2003**. A prevalidation study on the *in vitro* skin irritation function test (SIFT) for prediction of acute skin irritation *in vivo*: Results and evaluation of ECVAM Phase III. *Toxicology in Vitro* 17, 123–138.
11. Hoffmann J., Heisler E., Karpinski S., Losse J., Thomas D., Siefken W., Ahr HJ., Vohr HW., Fuchs HW. (**2005**). Epidermal-skin-test 1000 (EST-1,000)--a new reconstructed epidermis for *in vitro* skin corrosivity testing. *Toxicol In Vitro*. 2005 Oct;19(7):925-9.
12. Kandárová H., Hayden P., Klausner M., Kubilus J., Kearney P., Sheasgreen J. (**2009**) *In Vitro* Skin Irritation Testing: Improving the Sensitivity of the EpiDerm Skin Irritation Test Protocol. *Altern Lab Anim*. Dec;37(6):671-89
13. Kandárová H., Liebsch M., Genschow E., Ingrid Gerner, Traue D., Slawik B., Spielmann H., **2004**. *Optimisation of the EpiDerm Test Protocol for the upcoming ECVAM Validation Study on In Vitro Skin Irritation Tests*. *ALTEX* 21, 3/04, 107-114.
14. Kandárová, H., Liebsch, M., Gerner, I., Schmidt, E., Genschow, E., Traue, D., Spielmann, H., **2005**. EpiDerm Skin Irritation Test Protocol – Assessment of the performance of the optimized test. *ATLA* 33 (4), p. 351-367.
15. Mosman, T., **1983**. *Rapid colourimetric assay for cell growth and survival application to proliferation and cytotoxicity assays*. *Journal of Immunological Methods* 65, 55-63.
16. OECD, **2002**. *OECD Guideline for Testing of Chemicals, No. 404: Acute Dermal Irritation/Corrosion*. Organisation for Economic Cooperation and Development, Paris.
17. OECD, **2003**. *OECD Guideline for Testing of Chemicals, No. 431: In Vitro Skin Corrosion: Human Skin Model Test*. Organization for Economic Cooperation and Development, Paris, p.8.
18. OECD, **2010**. *OECD Guideline for Testing of Chemicals, No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method*

Version 5.2 September 2019	 In Vitro Skin Irritation	
Page 40 of 40	Standard Operating Procedure	

19. OECD. (2015). Performance Standards for the Assessment of Proposed Similar or Modified In vitro Reconstructed Human Epidermis (RhE) Test Methods for Skin Irritation in Relation to TG 439. Environment, health and Safety Publications, Series on Testing and Assessment (No. 220). Organisation for Economic Cooperation and Development, Paris.
20. Portes, P., Grandidier, M.-H., Cohen, C., Roguet, R., **2002**. *Refinement of the Episkin® protocol for the assessment of acute skin irritation of chemicals: follow-up to the ECVAM prevalidation study*. Toxicology in Vitro 16, 765-770.
21. Robinson, M.K., Cohen, C., de Brugerolle de Fraissinette, A., Ponec, M., Whittle, E., Fentem, J.H., **2002**. *Non-animal testing strategies for assessment of the skin corrosion and skin irritation potential of ingredients and finished products*. Food and Chemical Toxicology 40, 573-592.
22. Spielmann H., Hoffmann S., Liebsch M., Botham P., Fentem J.H., Eskes C., Roguet R., Cotovio J., Cole T., Worth A., Heylings J., Jones P., Robles C., Kandárová H., Gamer A., Remmele M., Curren R., Raabe H., Cockshott A., Gerner I, Zuang V. (**2009**). The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern Lab Anim. Dec; 35(6):559-601.
23. Van de Sandt, J., Roguet, R., Cohen, C., Esdaile, D., Ponec, M., Corsini, E., Barker, C., Fusenig, N., Liebsch, M., Benford, D., de Brugerolle de Fraissinette, A., Fartasch, M., **1999**. *The Use of Human Keratinocytes and Human Skin Models for Predicting Skin Irritation. The Report and Recommendations of ECVAM Workshop 38*. ATLA 27, 723-743.
24. Zuang, V., Balls, M., Botham, P.A., Coquette, A., Corsini, E., Curren, R.D., Elliott, G.R., Fentem, J.H., Heylings, J.R., Liebsch, M., Medina, J., Roguet, R., Van De Sandt, J.J.M., Wiemann, C., Worth, A.P., **2002**. *Follow up to the ECVAM prevalidation study on in vitro tests for acute skin irritation, ECVAM Skin Irritation Task Force Report 2*. ATLA 30, 109-129.
25. EURL ECVAM Scientific Advisory Committee (2016). ESAC Opinion on the validation study of the epiCS® Skin Irritation Test (SIT) based on the EURL ECVAM/OECD Performance Standards for in vitro skin irritation testing using Reconstructed human Epidermis (RhE). ESAC Opinion No. 2016-05 of 24 June 2016; EUR 28177 EN; doi:10.2787/64982. Available at: <http://publications.jrc.ec.europa.eu/repository/handle/JRC103707>
26. OECD, 2019. OECD Guideline for Testing of Chemical, No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method
27. ESAC Opinion on the Validation Study of the epiCS® Test Method based on the EURL ECVAM/OECD Performance Standards for in vitro Skin Irritation Testing using Reconstructed human Epidermis (RhE), ESAC Opinion Number 2016-0
28. Peer Review Report of the Validation of the Skin Irritation Tests Using Skin+® and Using epiCS® (2018)
29. EC Testing Method B.46. In vitro skin irritation: reconstructed human epidermis model test. Council Regulation (EC) No 761/2009